Pienaar Ilse S, Schallert Timothy, Hattingh Suzél, Daniels William M U
MRC Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK.
J Neural Transm (Vienna). 2009 Jul;116(7):791-806. doi: 10.1007/s00702-009-0247-4. Epub 2009 Jun 6.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastatin, is used for lowering elevated low-density lipoprotein cholesterol concentrations. This translates into reduced cardiovascular disease-related morbidity and mortality, while the drugs' anti-oxidant and anti-inflammatory properties have earmarked it as a potential treatment strategy against various neurological conditions. Statins have been shown to protect neurons from degeneration in a number of animal models. Although no mechanism completely explains the multiple benefits exerted by statins, emerging evidence suggests that in some degenerative and brain injury models, mitochondrial impairment may play a contributive rate. However, [corrected] evidence lacks to support a directly influencing role for statins on mitochondria-related proteins and motor behavior. Mitochondrial dysfunction may increase oxygen free radical production, which in turn leaves cells susceptible to energy failure, apoptosis and related events [corrected] which could prove fatal. The potential link between simvastatin treatment and mitochondrial function would be supported if key mitochondrial proteins were altered by simvastatin exposure. Using mass spectroscopy (MS), we identified 24 mitochondrial proteins that differed significantly (P < 0.05) in relative abundancy as a result of simvastatin treatment. The identified proteins represented many facets of mitochondrial integrity, with the majority forming part of the electron transport chain machinery, which is necessary for energy production. In a follow-up study, we then addressed whether simvastatin is capable of altering sensorimotor function in a mitochondrial toxin-induced animal model. Rats were pre-treated with simvastatin for 14 days, followed by a single unihemispheric (substantia nigra; SN) injection of rotenone, a mitochondrial complex I (Co-I) inhibitor. Results showed that simvastatin improved motor performance in rotenone-infused rats. The data are consistent with the possibility that alteration of mitochondrial function may contribute to the beneficial effects associated with statin use.
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂辛伐他汀用于降低升高的低密度脂蛋白胆固醇浓度。这转化为心血管疾病相关发病率和死亡率的降低,而该药物的抗氧化和抗炎特性使其成为针对各种神经系统疾病的潜在治疗策略。在许多动物模型中,他汀类药物已被证明可保护神经元免于退化。尽管没有一种机制能完全解释他汀类药物所带来的多种益处,但新出现的证据表明,在一些退行性和脑损伤模型中,线粒体损伤可能起到一定作用。然而,缺乏证据支持他汀类药物对线粒体相关蛋白和运动行为有直接影响作用。线粒体功能障碍可能会增加氧自由基的产生,进而使细胞易受能量衰竭、凋亡及相关事件的影响,而这些可能是致命的。如果辛伐他汀暴露能改变关键的线粒体蛋白,那么辛伐他汀治疗与线粒体功能之间的潜在联系将得到支持。通过质谱分析(MS),我们鉴定出24种线粒体蛋白,由于辛伐他汀治疗,它们的相对丰度有显著差异(P < 0.05)。所鉴定的蛋白代表了线粒体完整性的多个方面,其中大多数构成电子传递链机制的一部分,而电子传递链对于能量产生是必需的。在后续研究中,我们接着探讨辛伐他汀是否能够在一种线粒体毒素诱导的动物模型中改变感觉运动功能。大鼠先用辛伐他汀预处理14天,然后单半球(黑质;SN)注射鱼藤酮,一种线粒体复合体I(Co-I)抑制剂。结果显示,辛伐他汀改善了注射鱼藤酮大鼠的运动性能。这些数据与线粒体功能改变可能有助于他汀类药物使用所带来的有益效果这一可能性相一致。